Investment Thesis
IGC Pharma exhibits severe financial distress with minimal revenue ($519K), substantial operating losses ($4.8M), and negative operating cash flow ($3.5M) indicating approximately 3 months of cash runway. The company demonstrates failed or stalled commercialization with no clear path to profitability and critical going concern risk.
Strengths
- Conservative capital structure with minimal leverage (Debt/Equity of 0.02x) providing financial flexibility
- Positive stockholders equity of $8.1M providing some balance sheet cushion
- Gross margin of 48.7% indicates reasonable unit economics if commercialization succeeds
Risks
- Critical liquidity crisis with only $1.1M cash against $3.5M quarterly burn rate signaling imminent insolvency
- Minimal revenue generation against massive operating losses indicates failed product commercialization or pre-revenue status
- Negative operating and free cash flow coupled with low cash reserves suggests bankruptcy risk without immediate capital injection
Key Metrics to Watch
- Monthly cash burn trajectory and total months of operating runway remaining
- Revenue acceleration and achievement of commercial milestones or clinical trial outcomes
- Capital raise announcements, debt restructuring activities, or strategic alternatives including merger or acquisition
Financial Metrics
Revenue
519.0K
Net Income
-3.4M
EPS (Diluted)
$-0.04
Free Cash Flow
-3.5M
Total Assets
9.7M
Cash
1.1M
Profitability Ratios
Gross Margin
48.7%
Operating Margin
-925.6%
Net Margin
-659.0%
ROE
-42.3%
ROA
-35.1%
FCF Margin
-680.9%
Balance Sheet & Liquidity
Current Ratio
1.32x
Quick Ratio
0.89x
Debt/Equity
0.02x
Debt/Assets
16.9%
Interest Coverage
-2,402.00x
Long-term Debt
132.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T16:18:27.460085 |
Data as of: 2025-09-30 |
Powered by Claude AI